Abstract
Background
Liver fibrosis is a widespread chronic liver ailment linked to substantial mortality and limited therapeutic options. An in-depth comprehension of the genetic underpinnings of liver fibrogenesis is crucial for the development of effective management and treatment approaches.
Results
Using bioinformatics tools and the DisGeNET database, we pinpointed 105 genes significantly linked to liver fibrosis. Subsequently, we conducted functional assessments, incorporating gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and the STRING database, to construct protein–protein interaction networks (PPI) for these 105 liver fibrosis-associated genes. These analyses were executed via the WebGestalt 2019 online platform. We employed Cytoscape plugins, MCODE, and CytoHubba, to identify potential biomarker genes from these functional networks. Noteworthy hub genes encompassed TGF-β1, MMP2, CTNNB1, FGF2, IL6, LOX, CTGF, SMAD3, ALB, and VEGFA. TGF-β1 and MMP-2 exhibited substantial promise as liver fibrosis biomarkers, as denoted by their high systemic scores determined through the MCC algorithm in the CytoHubba methodology.
Conclusions
In summary, this study presents a robust genetic biomarker strategy that may prove invaluable in the identification of potential liver fibrosis biomarkers.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Universitas Riau, Master Program in Biomedical Sciences, Faculty of Medicine, Pekanbaru, Indonesia (GRID:grid.444161.2) (ISNI:0000 0000 8951 2213)
2 Universitas Ahmad Dahlan, Faculty of Pharmacy, Yogyakarta, Indonesia (GRID:grid.444626.6) (ISNI:0000 0000 9226 1101)
3 Universitas Riau, Department of Histology, Faculty of Medicine, Pekanbaru, Indonesia (GRID:grid.444161.2) (ISNI:0000 0000 8951 2213)
4 Universitas Muhammadiyah Mataram, Department of Pharmacy, Mataram, Indonesia (GRID:grid.443798.5) (ISNI:0000 0001 0179 6061)
5 Research Organization for Health, National Research and Innovation Agency (BRIN), Research Center for Vaccine and Drugs, South Tangerang, Indonesia (GRID:grid.443798.5)
6 Universitas Padjadjaran, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Sumedang, Indonesia (GRID:grid.11553.33) (ISNI:0000 0004 1796 1481); Universitas Padjadjaran, Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Sumedang, Indonesia (GRID:grid.11553.33) (ISNI:0000 0004 1796 1481)
7 Universitas Riau, Department of Medical Biology, Faculty of Medicine, Pekanbaru, Indonesia (GRID:grid.444161.2) (ISNI:0000 0000 8951 2213)
8 Universitas Muhammadiyah Mataram, Department of Pharmacy, Mataram, Indonesia (GRID:grid.443798.5) (ISNI:0000 0001 0179 6061); Research Organization for Electronics and Informatics, National Research and Innovation Agency (BRIN), Research Center for Computing, Cibinong, Indonesia (GRID:grid.443798.5)





